Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (DE:AWK1)
FRANKFURT:AWK1
RESEARCH TOOLSreports
Holding DE:AWK1?
Track your performance easily
See the Price Targets and Ratings of:
AWK1 Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AWK1 Stock 12 Month Forecast
Average Price Target
€22.11
▲(42.32% Upside)
| Highest Price Target€27.29 | Average Price Target€22.11 | Lowest Price Target€18.82 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Craig-Hallum
Assigned
03/05/24
Needham
Reiterated
03/05/24
H.C. Wainwright
Assigned
03/05/24
Leerink Partners
Reiterated
03/04/24
Oppenheimer
Reiterated
03/04/24
Piper Sandler
Reiterated
03/04/24
Ladenburg Thalmann & Co.
Reiterated
11/09/23
―
LifeSci Capital
―
Buy
―
Reiterated
03/04/24
This morning Avadel Pharmaceuc als (Nasdaq: AVDL) management reported $19.5M and $28.0M in revenue for Lumryz (once at bedme oxybate) in Q4 2023 and FY 2023, respecv ely. We are impressed by the progress achieved in ~7 months nong that the team began shipping products to customers in June 2023. It is clear Lumryz has had a healthy uptake and an impact on oxybate market dynamics, with more than 1,200 paen ts inia ng therapy as of end of January 2024. Jazz Pharmaceuc als (Nasdaq: JAZZ) reported flat QoQ growth for Xywav (twice-nightly low salt oxybate) in 44% reducon in Xyrem (twice-nightly sodium oxybate) sales in 2023. In addion, during the earnings call Jazz’s management team finally publicly acknowledged the impact of Lumryz on their twice nightly oxybate franchise. We expect these trends to connue into 2024 as Lumryz gains more market share.
Best Analysts Covering Avadel Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy DE:AWK1 and Sell After:
1 Month
xxx
Success Rate
13/23 ratings generated profit
Average Return
+7.55%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.52% of your transactions generating a profit, with an average return of +7.55% per trade.
3 Months
xxx
Success Rate
15/23 ratings generated profit
Average Return
+14.44%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +14.44% per trade.
1 Year
2 Years
xxx
Success Rate
18/18 ratings generated profit
Average Return
+140.87%
reiterated a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +140.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AWK1 Analyst Recommendation Trends
Rating
Nov 23
Dec 23
Jan 24
Feb 24
Mar 24
Strong Buy
9
9
8
2
5
Buy
4
4
4
5
8
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
13
12
7
13
Each month's total comprises the sum of three months' worth of ratings.
AWK1 Financial Forecast
AWK1 Stock Forecast FAQ
What is DE:AWK1’s average 12-month price target, according to analysts?
Based on analyst ratings, Avadel Pharmaceuticals’s 12-month average price target is €22.11.
What is DE:AWK1’s upside potential, based on the analysts’ average price target?
Avadel Pharmaceuticals has 42.32% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Avadel Pharmaceuticals a Buy, Sell or Hold?
Avadel Pharmaceuticals has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Avadel Pharmaceuticals’s share price target?
The average share price target for Avadel Pharmaceuticals is €22.11. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €27.29 ,and the lowest forecast is €18.82. The average share price target represents 42.32% Increase from the current price of €15.536.
The highest analyst share price target is €27.29 ,and the lowest forecast is €18.82. The average share price target represents 42.32% Increase from the current price of €15.536.
What do analysts say about Avadel Pharmaceuticals?
Avadel Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of Avadel Pharmaceuticals?
To buy shares of DE:AWK1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.